- Home
- UNCY
as 05-20-2024 4:00pm EST
Unicycive Therapeutics Inc is a biotechnology company dedicated to developing treatments for certain medical conditions. It is focusing on kidney diseases. The company's lead drug, Renazorb, is a novel phosphate-binding agent being developed for the treatment of hyperphosphatemia. Unicycive's other drug, UNI-494, is a new chemical entity with the issued composition of matter patent protection in late preclinical development for the treatment of acute kidney injury.
| Founded: | 2016 | Country: | United States |
| Employees: | N/A | City: | LOS ALTOS |
| Market Cap: | 41.0M | IPO Year: | 2021 |
| Target Price: | $5.50 | AVG Volume (30 days): | 394.9K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 5 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.19 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.47 - $1.82 | Next Earning Date: | 05-13-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Share on Social Networks:
Latest Unicycive Therapeutics Inc. News
UNCY Breaking Stock News: Dive into UNCY Ticker-Specific Updates for Smart Investing
GlobeNewswire
5 days ago
Unicycive Therapeutics Presents Bioequivalence Data on Oxylanthanum Carbonate (OLC) at the National Kidney Foundation Spring Clinical Meeting
GlobeNewswire
7 days ago
Unicycive Announces First Quarter 2024 Financial Results and Provides Business Update
TipRanks
21 days ago
These 2 ‘Strong Buy’ Penny Stocks Could Rally to $9, Says Piper Sandler
GlobeNewswire
a month ago
Unicycive Therapeutics to Present at the Noble Capital Markets Emerging Growth Virtual Healthcare Equity Conference
GlobeNewswire
2 months ago
Unicycive Therapeutics Announces Full Year 2023 Financial Results and Provides Business Update
GlobeNewswire
2 months ago
Unicycive Therapeutics to be Featured in Multiple Presentations at the Upcoming European Renal Association Congress
GlobeNewswire
2 months ago
Unicycive Announces $50 Million Private Placement
GlobeNewswire
2 months ago